These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18827610)

  • 1. Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument.
    Chen L; Antras L; Duh MS; Neary M; O'Brien ME
    J Thorac Oncol; 2008 Oct; 3(10):1137-45. PubMed ID: 18827610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer.
    Chen L; Antras L; Duh MS; Levy N; Neary M; O'Brien ME; von Pawel J
    Curr Med Res Opin; 2007 Nov; 23(11):2741-52. PubMed ID: 17900394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer.
    Riemsma R; Simons JP; Bashir Z; Gooch CL; Kleijnen J
    BMC Cancer; 2010 Aug; 10():436. PubMed ID: 20716361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
    Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
    J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.
    Ardizzoni A; Tiseo M; Boni L
    Eur J Cancer; 2014 Sep; 50(13):2211-8. PubMed ID: 24981975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
    O'Brien ME; Ciuleanu TE; Tsekov H; Shparyk Y; Cuceviá B; Juhasz G; Thatcher N; Ross GA; Dane GC; Crofts T
    J Clin Oncol; 2006 Dec; 24(34):5441-7. PubMed ID: 17135646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
    Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
    Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
    Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
    Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life.
    Gralla RJ
    Oncologist; 2004; 9 Suppl 6():14-24. PubMed ID: 15616146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan in the treatment of recurrent small cell lung cancer: an update.
    Ardizzoni A
    Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
    Socinski MA; Raju RN; Neubauer M; Smith DA; Richards DA; Savin M; Ruxer RL; Reynolds CH; Zhan F; Bromund JL; Chen R; Obasaju C
    J Thorac Oncol; 2008 Nov; 3(11):1308-16. PubMed ID: 18978567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial.
    Kurata T; Kashii T; Takeda K; Seki N; Tsuboi M; Kobayashi M; Satoh T; Nakagawa K; Fukuoka M
    J Thorac Oncol; 2009 May; 4(5):644-8. PubMed ID: 19325498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.
    Enomoto Y; Inui N; Imokawa S; Karayama M; Hasegawa H; Ozawa Y; Matsui T; Yokomura K; Suda T
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):499-505. PubMed ID: 26134440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.
    Garst J; Buller R; Lane S; Crawford J
    Clin Lung Cancer; 2005 Nov; 7(3):190-6. PubMed ID: 16354314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation.
    Hartwell D; Jones J; Loveman E; Harris P; Clegg A; Bird A
    Cancer Treat Rev; 2011 May; 37(3):242-9. PubMed ID: 20709456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan.
    Tiseo M; Buti S; Boni L; Mattioni R; Ardizzoni A
    Lung Cancer; 2014 Oct; 86(1):91-5. PubMed ID: 25130081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of the Assessment of Quality of Life (AQoL) utility instrument in patients with operable and inoperable lung cancer.
    Manser RL; Wright G; Byrnes G; Hart D; Conron M; Carter R; McLachlan SA; Campbell DA
    Lung Cancer; 2006 Aug; 53(2):217-29. PubMed ID: 16765475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New advances in the second-line treatment of small cell lung cancer.
    Hurwitz JL; McCoy F; Scullin P; Fennell DA
    Oncologist; 2009 Oct; 14(10):986-94. PubMed ID: 19819917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.